SMI 6860766 

SMI 6860766, a small molecule inhibitor of CD40-TRAF6 interaction, improves glucose tolerance, reduces immune cell accumulation in adipose tissue, and reduces AT inflammation^[1].

SMI 6860766 (0-100 μM; 1 h) dose-dependently suppresses CD40-induced gene expression of IL-1β and IL-6 cytokines in BM-derived macrophages^[1].
SMI 6860766 reduces the levels of CCL2 in CD40+/+, CD40-Twt and CD40-TRAF2/3/5−/− macrophages^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SMI 6860766 increases the number of adipocytes per field of view by 15.3% in mouse EpAT, indicating that SMI reduces adipocyte size, indicating reduces lipid storage and improves metabolic function^[1].
SMI 6860766 reduces the number of total leukocytes (CD45+ cells) in mouse EpAT by 68.5%^[1].
SMI 6860766 does not induce differences in hepatosteatosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

336.61

C₁₅H₁₁BrClNO

433234-16-3

O=C(C1=CC=CC=C1)/C=C/NC2=CC=C(Br)C=C2Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Van den Berg SM, et al. Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. Int J Obes (Lond). 2015 May;39(5):782-90.  [Content Brief]